This list of clinical research protocols relating to prostate cancer is compiled for your convenience.

VA-CSP-407, NCI-T94-0131O, PIVOT-1, CLB-949 High Priority Clinical Trial Phase III Randomized Study of Prostatectomy vs Expectant Observation With Palliative Therapy for Stage I/II Prostate Cancer (PIVOT).


MRC-PR05, EU-94033 Phase III Randomized Double-Blind Study of Clodronate vs Placebo in Patients With Prostate Cancer Metastatic to Bone Who Are Commencing or Responding to Initial Hormone Therapy.


PROG-9509 Phase III Randomized Study of Conventional vs High-Dose Radiotherapy Using Conformal Photons With a Proton Boost in Stage I/II Prostate Cancer.


CWRU-1894, NCI-G97-1360 Phase III Study of Adjuvant Estramustine and Etoposide vs Observation Following Radical Prostatectomy for Stage II, III, or IV Prostate Cancer.


AG-3340-009 Phase III Randomized Study of Matrix Metalloproteinase Inhibitor AG3340 in Combination With Mitoxantrone and Prednisone in Patients With Hormone Refractory Prostate Cancer.


CLB-9583 Phase III Randomized Study of Antiandrogen Withdrawal Alone vs Antiandrogen Withdrawal Plus Ketoconazole and Hydrocortisone for Hormone-Refractory Prostate Cancer.


MRC-RT01, EU-98005 Phase III Randomized Comparison Study of Conformal Standard Radiotherapy vs Conformal High Dose Radiotherapy in Addition to Neoadjuvant Androgen Deprivation in Patients With Localized Prostate Cancer.


MDA-DM-95231, NCI-G96-1044 Phase III Study of Chemo/Hormonal Therapy vs Androgen Ablation Alone as Initial Therapy in Unresectable/Metastatic Adenocarcinoma of the Prostate.

E-8892, CLB-E8892 Phase III Randomized Study of Orchiectomy or LHRH Analogue Plus Flutamide With vs Without Suramin and Hydrocortisone in Advanced Adenocarcinoma of the Prostate.


CAN-NCIC-PR3, NCI-T94-01100, E-JPR03 Phase III Randomized Study of Total Androgen Blockade With vs Without Pelvic Irradiation for Stage T3-4, N0, M0 Adenocarcinoma of the Prostate.


EORTC-30846 Phase III Immediate vs Delayed Endocrine Therapy With Zoladex and Cyproterone Acetate for Patients With pN1-3M0 Carcinoma of the Prostate.


EORTC-30921 Phase III Randomized Trial of Strontium-89 vs Palliative Local Radiotherapy in Patients With Hormone-Refractory Prostate Cancer With Painful Osseous Metastases.


EORTC-30972 Phase III Randomized Study of Prednisone Alone or in Combination With BMS-182751 in Patients With Advanced Hormone Refractory Adenocarcinoma of the Prostate.


EORTC-30891 Phase III Comparison of Early vs Delayed Endocrine Manipulation (Orchiectomy or LHRH Agonist Therapy) in Previously Untreated Patients With Nonmetastatic Asymptomatic carcinoma of the Prostate.


CAN-NCIC-PR6 Phase III Randomized Study of Mitoxantrone and Prednisone With or Without Clodronate in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain.


EORTC-22961 Phase III Study of Long Term Adjuvant Hormonal Treatment With LHRH Analogue (Goserelin) vs No Further Treatment in Locally Advanced Prostatic Carcinoma Treated by External Irradiation and a Six Month Combined Androgen Blockade.


EORTC-22911 Phase III Randomized Study of Postoperative External Radiotherapy vs No Immediate Further Treatment in Patients With pT3 pN0 Prostatic Adenocarcinoma.


SWOG-9346, CLB-9594, INT-0162, E-S9346 Phase III Randomized Study of Intermittent vs Constant Combined Androgen Deprivation (Flutamide/Leuproline or Flutamide/Goserelin) in Stage D2 Prostate Cancer Responsive to Such Therapy.


RTOG-9601, RTOG-R9601, SWOG-R9601 Phase III Randomized, Double-Blind Study of Radiotherapy With or Without Bicalutamide in Patients With PSA Elevation Following Radical Prostatectomy for pT3 N0 Carcinoma of the Prostate.


RTOG-9608 Phase III Study of Total Androgen Suppression vs Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive Adenocarcinoma of the Prostate.


RTOG-9714, NCI-P97-0124, NCCTG-R9714 Phase III Randomized Study of Palliative Radiation Therapy for Bone Metastases From Breast or Prostate Cancer.

RTGO-9413 Phase III Randomized Study of Whole-Pelvic Irradiation Followed by a Cone-Down Boost to the Prostate vs Prostate Irradiation Only and of Neoadjuvant vs Adjuvant FLUT/ZDX for Adenocarcinoma of the Prostate.


RTGO-9408 Phase III Randomized Study of Radiotherapy With vs Without Neoadjuvant Flutamide/ Goserelin in Good-Prognosis, Locally Confined Adenocarcinoma of the Prostate.


Legend for Abbreviations:

AG = Agouron Pharmaceuticals, Inc
CAN-NCIC = National Cancer Institute of Canada
CAN-OCOG = Ontario Clinical Oncology Group
CLB = Cancer & Leukemia Group B
CWRU = Case Western Reserve University
E, EST = Eastern Cooperative Oncology Group
EORTC = European Organization for Research on Treatment of Cancer
MRC = United Kingdom Medical Research Council
MSKCC = Memorial Sloan-Kettering Cancer Center
PROG = Proton Radiation Oncology Group
RPCI = Roswell Park Cancer Institute
RTOG = Radiation Therapy Oncology Group
SWOG = Southwest Oncology Group
VA = Veterans Administration Cooperative Studies Program

Back to Cancer Control Journal Volume 5 Number 6